GSK's depemokimab shows promise in Phase III trials for chronic rhinosinusitis

By Yahoo! Finance | Oct 15, 2024 at 05:42 AM EST

GSK's Phase III trials of depemokimab in CRSwNP patients showed significant improvements compared to placebo, meeting primary endpoints. The drug's potential as a convenient treatment option is promising, with regulatory filings supported by positive trial data.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.